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Abstract
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic
leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase
activity. The constitutively activated BCR/ABL-kinase “escapes” the auto-inhibition mechanisms of c-ABL, such as
allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding
site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR/ABL restores allosteric
inhibition. Given the fact that all AKIs fail to inhibit BCR/ABL harboring the ‘gatekeeper’ mutation T315I, we
investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.
Methods: The efficacy of this approach on the leukemogenic potential of BCR/ABL was studied in Ba/F3 cells,
primary murine bone marrow cells, and untransformed Rat-1 fibroblasts expressing BCR/ABL or BCR/ABL-T315I as
well as in patient-derived long-term cultures (PDLTC) from Ph + ALL-patients.
Results: Here, we show that GNF-2 increased the effects of AKIs on unmutated BCR/ABL. Interestingly, the
combination of Dasatinib and GNF-2 overcame resistance of BCR/ABL-T315I in all models used in a synergistic
manner.
Conclusions: Our observations establish a new approach for the molecular targeting of BCR/ABL and its resistant
mutants using a combination of AKIs and allosteric inhibitors.
Keywords: Philadelphia chromosome, BCR/ABL, “gatekeeper” mutation T315I, Allosteric inhibition, Abl kinase
inhibitors, Molecular therapy
Background
Chronic myeloid leukemia (CML) and 30% of adult
acute lymphatic leukemia (ALL) are characterized by the
Philadelphia chromosome (Ph+), which is the cytogen-
etic correlate of the (9;22) chromosomal translocation.
The t(9;22) leads to the fusion of the breakpoint cluster
region (BCR) gene and the Abelson tyrosine kinase
(ABL1). BCR/ABL results in a deregulated and constitu-
tively activated tyrosine kinase, which is responsible for
the induction of the phenotype of Ph + leukemia. BCR/
ABL constitutively activates several signaling pathways
leading to uncontrolled proliferation and inhibition of
apoptosis. The expression of BCR/ABL is sufficient for
the initiation and maintenance of early stage CML and
the “CML-like disease” in mice [1,2].
Selective targeting of BCR/ABL by ABL-kinase inhibi-
tors (AKI) such as Imatinib, Nilotinib or Dasatinib, all
competitive ATP-analogues, leads to durable cytogenetic
and molecular remissions in the majority of CML
patients in the early chronic phase of the disease. How-
ever, unsatisfactory responses in advanced disease stages,
resistance and long-term tolerability of BCR/ABL inhibi-
tors represent major clinical problems. In fact, advanced
CML and Ph + ALL respond only transiently to AKIs
[3,4]. Secondary resistance is mostly caused by the
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fere with the affinity for these ATP competitors. The
second-generation inhibitors Nilotinib and Dasatinib tar-
get most resistant BCR/ABL mutants [5,6] with the ex-
ception of the “gatekeeper” mutation T315I. T315I is the
most clinically relevant mutation because it confers a
global resistance against all available molecular therapy
approaches [3,4].
The activation status of wild-type c-ABL is finely regu-
lated by several regulation signals. Myristoylation of the
N-terminus of c-ABL is involved in the regulation of the
ABL kinase activity. The N-terminus of ABL is myristoy-
lated, and the myristate residue binds to a hydrophobic
pocket in the kinase domain - the myristoyl-binding
pocket (MBP) – in a process called “capping”. The “cap-
ping” leads to conformational changes that allow the
intramolecularly docking of the “SRC homology 2 do-
main” to the kinase domain. Hence, c-ABL adopts an
auto-inhibited conformation. The absence of an N-
terminal myristoylated domain activates c-ABL consist-
ent with its auto-regulatory role. In the context of the t
(9;22), the N-terminal auto-inhibitory “Cap” region is
substituted by the BCR portion of the fusion protein.
The absence of the “Cap” region allows the BCR/ABL to
“escape” auto-inhibition contributing to the constitutive
activation of its kinase activity [7].
We have recently shown that the allosteric inhibition
increases the sensitivity of BCR/ABL-T315I towards the
inhibition of oligomerization most likely by interfering
with the overall confirmation of the kinase [4]. Given
the fact that the resistance against AKIs in the BCR/
ABL-T315I mutant is a problem of the accessibility of
the ATP-binding site in the kinase domain, we analyzed
the influence of the allosteric inhibition on the response
of BCR/ABL-T315I towards AKIs. Preliminary data
showed the best effect for Dasatinib compared to Niloti-
nib or Imatinib. Therefore, we analyzed whether it was
possible to enhance the response and to overcome the
resistance of the BCR/ABL-T315I mutant by combining
the allosteric inhibition of GNF-2 with Dasatinib.
Methods
Plasmids
The cDNAs encoding BCR/ABL and BCR/ABL-T315I
have been previously described (3). All retroviral expres-
sion vectors used in this study were based on the bi-
cistronic PINCO vector.
Cell lines and patient-derived long-term cultures
The Ba/F3 and Rat-1 cells were obtained from the Ger-
man Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany) and were maintained
as previously described (3). Ph + ALL patient derived
long term cultures (PDLTCs) expressing BCR-ABL-
T315I (KÖ) were obtained from a patient enrolled in
the German Multi-Center Study Group for acute lymph-
atic leukemia of the adult (GMALL 07/2003) upon
informed and written consent [8] and were maintained
in a serum–free medium consisting of IMDM supple-
mented with 1 mg/mL of bovine insulin, 5x10
-5 M
β–mercaptoethanol (Sigma, Steinheim, Germany),
200 mg/mL Fe –saturated human apo–transferrin
(Invitrogen, Karlsruhe, Germany), 0.6% human serum
albumin (Sanquin, Amsterdam, The Netherlands),
2.0 mM L–glutamine and 20 mg/mL cholesterol
(Sigma) [9]. Proliferation was assessed with the XTT
proliferation kit (Roche, Mannheim, Germany) accord-
ing to the manufacturer’s instructions.
Isolation of Sca1
+/lin
- hematopoietic stem and progenitor
cells (HSPCs)
Sca1
+/lin
- HSPCs were isolated from 8- to 12-week-old
female C57BL/6 N mice (Janvier, St. Berthevin, France)
after euthanization by CO2 asphyxiation. Bone marrow
(BM) was harvested from the femur and tibia by flushing
the bones with a syringe and a 26-gauge needle. Sca1
+
cells were purified by immunomagnetic beads using
MACS cell separation columns according to the manu-
facturer’s instructions (Miltenyi, Bergisch-Gladbach,
Germany). Prior to subsequent use, the purified cells
were pre-stimulated for 2 days in DMEM supplemented
with 10% FCS (Hyclone/Perbio Science, Bonn Germany),
1% L-Glutamine, 1% Penicillin/Streptomycin, mIL-3
(20 ng/mL), mIL-6 (20 ng/mL) and mSCF (100 ng/mL)
(Cell Concepts, Umkirch, Germany).
Transfection and retroviral infection
Ecotropic retroviral supernatants were obtained after
transfection of Phoenix packaging cells as described earl-
ier [3]. For infection of target cells, Retronectin
W (Takara
Bio Inc., Otsu, Japan) was used to enhance infection effi-
ciency according to the manufacturer’s instructions.
Then, 2x10
5 target cells were seeded per well. Infection
efficiency was measured after 48 h by determining the
percentage of GFP positive cells using flow cytometry.
Transformation assays
Soft agar and focus formation assays were performed
using untransformed Rat-1 fibroblasts retro virally trans-
duced with PINCO vectors harboring unmutated BCR/
ABL or BCR/ABL-T315I. Six-well plates were filled with
DMEM supplemented with 10% FCS and 0.5% bacto-
agar (DIFCO Laboratories, Detroit, MI, USA) (2 ml per
well). Then, 5x10
3 transduced Rat-1 cells were sus-
pended in “top-agar” (DMEM supplemented with 10%
FCS and 0.25% bacto-agar) (1 ml per well) and stacked
in the wells. Colonies were counted after 15 days of in-
cubation at 37°C and 5% CO2. For focus formation
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4 transduced Rat-1 cells were plated per well
of a 24-well plate. Foci were stained after 15 days using
1% crystal violet (Sigma).
Colony assays on HSPCs
At day 5 post-infection, Sca1
+ cells were plated at 5x10
3
cells/mL in methyl-cellulose either with mIL-3 (20 ng/
mL), mIL-6 (20 ng/mL) and mSCF (100 ng/mL) or with-
out cytokines (Stem Cells Inc., Cambridge, UK). The
number of colony forming units (CFUs) was determined
10 days after plating and normalized according to the
transduction efficiency.
Western blotting
Western blot analysis was performed according to
widely accepted protocols. The following antibodies were
used: anti-ABL (α-ABL) (St. Cruz Biotechnology, Santa
Cruz, CA, USA), anti-phosphorylated ABL specific for
the phosphorylated tyrosine residue 245 (α-p-ABL-Y245)
(Cell Signaling, Boston, MA, USA), anti-BCR (α-BCR)
(St. Cruz Biotechnology), anti-phosphorylated BCR spe-
cific for the phosphorylated tyrosine residue 177 (α-p-
BCR-Y177), anti-Crkl, and anti-phosphorylated Crkl
(Cell Signaling).
Statistical analysis
Differences in response rates towards different concen-
trations of a single inhibitor or inhibitors in combination
were analyzed by Student0s t-tests. Statistical analyses
were performed using the GraphPad Prism (GraphPad
Software, San Diego, CA) software package. Evaluation
of the character of the combined effects was performed
according to the three dimensional model of Prichard
and Shipman using MacSynergy software [10].
Results
The allosteric inhibitor GNF-2 improves the response of
unmutated BCR/ABL to AKIs
Unmutated BCR/ABL can be efficiently inhibited not
only by AKIs but also by allosteric inhibitors such as
GNF-2 or GNF-5 [4,11,12]. To determine whether the
allosteric inhibition can improve the response of BCR/
ABL-positive cells to AKIs, we exposed Ba/F3 cells pre-
viously rendered factor-independent by the expression of
BCR/ABL to Dasatinib and GNF-2 at concentrations of
5 to 100 nM and 0.1 to 0.4 μM, respectively, upon factor
withdrawal. Proliferation/cytotoxicity was assessed by an
XTT assay. Ba/F3 cells transduced with empty vector in
the presence of mIL-3 were used as a control. As shown
in Figure 1, GNF-2 and Dasatinib only affected growth
of control cells at the very highest concentrations ex-
cluding an unspecific cytotoxic effect of the compounds
and their combination (Figure 1). The combination with
GNF-2 accelerated and intensified the effects of
Dasatinib on the BA/F3-BCR/ABL cells, suggesting a
combinatorial effect upon factor withdrawal in these
cells (Figure 1).
Taken together, these data suggest that the inhibition
effect of Dasatinib is enhanced by GNF-2 in cells expres-
sing unmutated BCR/ABL.
The combination of GNF-2 with dasatinib efficiently
abolishes the BCR/ABL-T315I-mediated factor-
independent growth of Ba/F3 cells
The major clinical challenge in Ph + leukemia is the
drug resistance due to the “gatekeeper” mutation T315I.
T315I confers a nearly global resistance to all molecular
therapy approaches that target BCR/ABL. Neither GNF-
2 nor AKIs have any effect on cells transformed by
BCR/ABL-T315I. To analyze whether the combination
of allosteric inhibition with AKIs is able to inhibit BCR/
ABL-T315I, we exposed Ba/F3 cells expressing BCR/
ABL-T315I to increasing concentrations of Dasatinib
(0.3, 0.6, 1.25, 2.5 and 5 μM) and GNF-2 (0.3, 0.6, 1.25,
2.5 and 5 μM). Cytotoxicity and proliferation were
assessed by the XTT assay. Here, we show that only the
combination of GNF-2 and Dasatinib inhibited BCR/
ABL-T315I-dependent cell growth with a very high syn-
ergy index of 186 (calculated combination index)
(Figure 2A-C), whereas Dasatinib alone inhibited growth
only at the very highest concentrations. For example, at
a GNF-2 concentration of 2 μM, Dasatinib inhibits
BCR/ABL-T315I-dependent proliferation with an IC50
of 300 nM without affecting Ba/F3 control cells
(Figure 2C). This effect is due to the capacity of the two
compounds to efficiently reduce the autophosphoryla-
tion of BCR/ABL (Figure 2A).
Taken together, these data suggest that the allosteric
inhibition sensitizes BCR/ABL cells harboring the “gate-
keeper” mutation T315I towards the ATP analogue
Dasatinib.
The combination of GNF-2 and dasatinib inhibited the
growth of Ph + lymphatic PDLTCs expressing BCR/ABL-
T315I
Ph + ALL expressing BCR/ABL-T315I is not fully
represented in cell lines. Therefore, we tested the re-
sponse of PDLTCs from Ph + ALL patients expressing
BCR/ABL-T315I to GNF-2 and Dasatinib. The PDLTCs
were directly derived from BM cells of Ph + ALL
patients cultured in a specific culture medium [9]. We
recently established a novel PDLTC from a Ph + ALL
patient harboring the BCR/ABL-T315I (KÖ) [8]. In this
PDLTC, 50% of the cells harbor the BCR/ABL-T315I
whereas the other 50% express unmutated BCR/ABL.
We analyzed the response of increasing concentrations
of PDLTCs from Ph + ALL patients expressing BCR/
ABL-T315I (KÖ) to drug combinations. As negative
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(HP). Cytotoxicity and proliferation were assessed at
72 h by XTT. At the dosages used, non-specific
cytotoxic effects were not observed in the Ph- HP cells
(Figure 3). Regarding the KÖ cells, the effects of GNF-2
and Dasatinib alone are attributable to the response of
the 50% of the cell population, which express the
unmutated BCR/ABL. The combination of GNF-2 and
Dasatinib overcame the 50% effects of the single
compounds and inhibited the proliferation of BCR/
ABL-T315I-expressing PDLTCs with IC50 values of 1-
1.25 μM and 100 nM (Figure 3).
Figure 1 Effects of the allosteric inhibitor (GNF-2) and Abl kinase inhibitor (Dasatinib) on Ba/F3 cells expressing unmutated BCR/ABL.
(A) XTT assay using Ba/F3 cells expressing empty vector upon exposure to 0.3, 0.6, 1.25, 2.5 and 5 μM GNF-2 and 0.3, 0.6, 1.25, 2.5 and 5 μM
Dasatinib. (B) XTT assay using Ba/F3 cells expressing BCR/ABL upon exposure to 0.1, 0.2 and 0.4 μM GNF-2 and 5, 10, 25, 50 and 100 nM
Dasatinib. Proliferation status was determined by the metabolic activity of cells given by the reduction rate of XTT to formazan. The means +/- SD
of triplicates from one representative experiment out of three performed are given.
Figure 2 Effects of the allosteric inhibitor (GNF-2) and Abl kinase inhibitor (Dasatinib) on Ba/F3 cells expressing “gatekeeper” mutation
T315I. (A) XTT assay using Ba/F3 cells expressing BCR/ABL-T315I upon exposure to 0.3, 0.6, 1.25, 2.5 and 5 μM GNF-2 and 0.3, 0.6, 1.25, 2.5 and
5 μM Dasatinib. Proliferation status was determined by the metabolic activity of cells given by the reduction rate of XTT to formazan. The means
+/- SD of triplicates from one representative experiment out of three performed are given. (B) Western blot analysis of Ba/F3 cells expressing the
indicated transgenes using antibodies directed against the indicated proteins. (C) Calculation of the combined effect by the MacSynergy
program.
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allosteric inhibition and Dasatinib overcomes the resist-
ance in primary PDLTCs from Ph + ALL patients har-
boring the BCR/ABL-T315I mutation.
The combination of allosteric inhibition and dasatinib
is able to abolish the transformation potential of
BCR/ABL-T315I
We have shown recently that GNF-2 inhibits the trans-
formation potential of unmutated BCR/ABL but not of
BCR/ABL-T315I in untransformed fibroblasts [4].
Therefore, we asked the question of whether the com-
bination of GNF-2 with Dasatinib is able to inhibit the
transformation potential of BCR/ABL-T315I. The
transformation potential of BCR/ABL-T315I in the pres-
ence of GNF-2 +/- Dasatinib was assessed using classical
transformation assays for the detection of contact inhib-
ition and anchorage-dependent growth in untransformed
Rat-1 fibroblasts. Thus, we retro virally expressed BCR/
ABL-T315I in Rat-1 cells. Empty-vector-transduced Rat-
1 cells (mock) were used as controls. The transduction
efficiency was assessed by the detection of GFP using
flow cytometry. For each construct, triplicates of 10
3
infected Rat-1 cells were placed on soft agar (anchorage-
dependent growth) and in 6-well plates for the focus for-
mation assay (contact inhibition). Colonies and “foci”
stained with crystal violet were counted after 15 days. As
shown in Figure 4A, only the combination of GNF-2
Figure 3 Effects of GNF-2 and Dasatinib on PDLTCs of Ph + ALL patients expressing BCR/AB-T315I. Proliferation/citotoxicity was
determined by the metabolic activity of cells given by the reduction rate of XTT to formazan. The means +/- SD of triplicates from one
representative experiment out of three performed are shown. (A) XTT assay using Ph- PDLTCs (HP) upon exposure to 1.25, 2.5 and 5 μM GNF-2
and 125, 25 and 500 nM Dasatinib. (B) XTT assay using Ph + PDLTCs (KÖ) expressing BCR/ABL-T315I upon exposure to 1.25, 2.5 and 5 μM GNF-2
and 125, 250 and 500 nM Dasatinib.
Figure 4 Effects of GNF-2 and Dasatinib on Rat-1 cells expressing BCR/ABL-T315I. (A) Transformation assays measuring colony formation in
soft agar. Rat-1 cells were retrovirally transduced with the BCR/ABL-T315I construct and seeded at 10
4 cells/well on soft agar in six-well plates in
the presence of 2.5 or 5 μM GNF-2 and 300 nM Dasatinib. After 15 days, the colonies were counted. The means +/- SD of triplicates of two
representative experiments are presented. (B) Focus formation assays. A total of 4x10
4 infected Rat-1 cells were plated per well in 24-well plates,
grown for 72 h to confluence and incubated for 12 additional days in the presence of 2.5 or 5 μM GNF-2 and 300 nM Dasatinib. The plates were
then washed, dried and stained with crystal violet. One representative of each of the two experiments performed in triplicate is given (34X
magnification).
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and restore contact inhibition in Rat-1 cells expressing
BCR/ABL-T315I (Figure 4A and B).
These data indicate that the combination of allosteric
inhibitors with AKIs inhibits the transformation poten-
tial of BCR/ABL-T315I.
GNF-2 cooperates with dasatinib to inhibit colony
formation of hematopoietic stem and progenitors cells
(HSPCs) harboring BCR/ABL-T315I in semi-solid medium
To further confirm the synergistic effect of the combin-
ation of Dasatinib and GNF-2, we extended our investi-
gation to a model of primary murine hematopoietic
stem and progenitor cells expressing BCR/ABL. We
studied the effects of the drug combination on the col-
ony formation by BCR/ABL cells in semi-solid medium
in the presence or absence of cytokines (mIL-3, mSCF
and mIL-6). We transduced Sca1
+ HSPCs with BCR/
ABL-T315I, and plated the cells in methyl-cellulose with
increasing concentrations of GNF-2 and Dasatinib. As
shown in Figure 5A, colony formation was inhibited by
Dasatinib and GNF-2 at concentrations of 300 nM and
2.5 μM, respectively, in the presence of cytokines. Inter-
estingly, in the absence of cytokines, BCR/ABL-T315I
formed compact colonies, which were inhibited effi-
ciently with the combination of Dasatinib and GNF-2 at
300 nM and 2.5 μM, respectively (Figure 5B).
These data demonstrate that mHPSCs expressing the
“gatekeeper” mutation T315I can be targeted efficiently
by the combination of GNF-2 and Dasatinib.
Discussion
The major therapeutic challenge in Ph + leukemia is to
efficiently treat patients with BCR/ABL harboring the
T315I mutation. The T315I mutation is the most resist-
ant to inhibition because of a combination of several fac-
tors, including steric hindrance of drug binding, loss of a
key hydrogen-bonding interaction with the T315 side-
chain hydroxyl group exploited by Imatinib, Nilotinib
and Dasatinib and potentially through increasing aber-
rant intrinsic kinase activity accompanied by aberrant
substrate phosphorylation [13,14]. Unfortunately, T315I
confers resistance not only against ABL kinase inhibitors
but also against the allosteric inhibition by GNF-2 [11].
Allosteric inhibition is a novel approach for targeting
BCR/ABL, which overcomes the resistance mediated
by the T315I in combination with inhibition of
oligomerization [4]. The fact that the competitive pep-
tides for oligomerization inhibition are still far from
clinical application led us to explore whether the allo-
steric inhibition could also improve the response of
BCR/ABL-T315I to competitive ATP analogues.
GNF-2 and its analogues are non-ATP competitive
ABL kinase inhibitors, which bind to the MBP in the
kinase domain. It seems that the binding of GNF-2 to
the MBP stabilizes the protein in an inhibited conform-
ation resulting in a structural reorganization of ABL that
disrupts the catalytic machinery located in the ATP-
binding region [7]. Thus, one can speculate that GNF-2
introduces changes in the overall conformations of BCR/
ABL-T315I, which renders the ATP-binding site more
accessible to Dasatinib. This result is confirmed by re-
cent biophysical studies showing that Dasatinib induces
conformational changes in unmutated BCR/ABL but not
in BCR/ABL-T315I. In contrast, GNF-5 leads to the
same changes in both unmutated BCR/ABL and BCR/
ABL-T315I [15].
An additive but not synergistic effect was shown for
the combination of Nilotinib with GNF-2 or GNF-5 on
BCR/ABL-T315I-related resistance. The stronger effects
may be attributed to the fact that Dasatinib, originally
developed as a SRC-kinase inhibitor, not only inhibits
the BCR/ABL kinase but also targets a broader range of
kinases compared to Nilotinib, the spectrum of which is
mainly limited to ABL, c-KIT and PDGFR [16]. An add-
itional effect of GNF-2 itself on SRC family kinases is
Figure 5 Effects of GNF-2 and Dasatinib on HSPCs expressing BCR/ABL-T315I. Sca1+ BM cells were retrovirally infected with BCR/ABL-T315.
Infected cells were then plated in semi-solid medium in the presence of 2.5 or 5 μM GNF-2 and 0.3 or 0.6 μM Dasatinib (A) without cytokines
and (B) with cytokines (mIL-3, mIL-6 and mSCF) to determine the effect of the drugs on HSPC colony formation in semi-solid medium. Colonies
were counted after 10 days. The means +/- SD of triplicates from one representative experiment out of two performed are given.
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tive MBP, which is involved in the regulation of c-SRC
kinase activity, but in a manner very different from that
for c-ABL [17].
Our data further establish allosteric inhibition as alter-
native or additional molecular therapy approach for the
treatment of Ph
+ leukemia. In fact, it not only overcomes
the resistance mediated by the “gatekeeper” mutation
T315I but also increases the response of unmutated
BCR/ABL to AKI. In the clinical setting, this feature
could contribute to a more efficient use of AKI at a
lower dosage in “normally” responsive patients and the
possibility to further increase dosage in patients early in
the progression of disease, in the absence of BCR/ABL
mutations, for whom dosage escalation is still a thera-
peutic option.
The results presented here contribute to the further
development of allosteric inhibition for the molecular
targeting of both unmutated BCR/ABL and BCR/ABL
harboring the multi-resistance mutation T315I.
Conclusions
Resistance and long-term tolerability of BCR/ABL inhi-
bitors represent the major therapeutic challenge in
Philadelphia Chromosome-positive (Ph+) leukemia.
Advanced Ph + leukemia respond only transiently to
ABL kinase inhibitors (AKI). Resistance is mostly caused
by the acquisition of point mutations in BCR/ABL. The
“gatekeeper” mutation T315I confers resistance against
all available molecular therapy approaches. Conform-
ational changes by allosteric inhibition increases the re-
sponse of both unmutated BCR/ABL and BCR/ABL-
T315I towards inhibition of oligomerization. Therefore
we investigated whether the conformational changes
induced by the allosteric inhibition also enhances the
response towards the AKI Dasatinib in clinically relevant
models of Ph + leukemia. Allosteric inhibition not only
increased the response of unmutated BCR/ABL to Dasa-
tinib but also contributed to overcome resistance of
BCR/ABL-T315I in a synergistic manner in all models
used.
Therefore allosteric inhibition may contribute to the
optimization of the therapy of patients with both unmu-
tated BCR/ABL or harboring resistance mutations such
as the T315I.
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